Accelrys and eMolecules Collaborate to Enhance Accelrys Available Chemicals Directory
News Apr 06, 2013
Accelrys, Inc., a leading provider of scientific innovation lifecycle management software, and eMolecules, Inc, a market-leading compound sourcing platform, announced that they are collaborating to include eMolecules' in-stock building block compounds in the Accelrys Available Chemicals Directory (ACD) database. Adding eMolecules into Accelrys ACD enables scientists to identify the optimal set of compounds for their synthesis or library with increased confidence that those compounds will be available at the indicated prices from the selected suppliers.
"Now, with the inclusion of validated and curated compound availability information from eMolecules, Accelrys ACD customers can order with increased confidence that chemical suppliers will deliver the compounds on time," said Dr. Matt Hahn , senior vice president and chief technology officer, Accelrys. "Together, Accelrys and eMolecules are revolutionizing the efficiency and reliability of compound acquisition throughout our shared markets."
"This collaboration will help Accelrys ACD users acquire the in-stock compounds critical to their projects' progress in an efficient and easy way," said Niko Gubernator , CEO of eMolecules. "eMolecules is excited to demonstrate to Accelrys' ACD users how our revolutionary approach to compound purchasing has delivered industry-proven results in improving efficiencies, lowering costs and driving innovation for pharmaceutical, biotech and academic groups alike."
The eMolecules online chemical compound sourcing platform has rapidly established itself as a market leader in enabling scientists to source and purchase commercially available 'in-stock' compounds reliably and efficiently. Accelrys ACD, used and trusted for more than 25 years by researchers in the global pharmaceutical, biotechnology, chemical and agrochemical sectors, enables scientists to access high quality curated and harmonized chemical property, availability and pricing information on 7.8 million compounds from 940 suppliers, with the information available via numerous delivery mechanisms including remotely hosted services.
As a result of the collaboration between Accelrys and eMolecules, ACD compounds now include more than 580,000 in-stock building blocks from more than 200 trusted eMolecules suppliers. With the inclusion of the unique eMolecules compound identifiers in ACD, and the equivalent unique ACD identifiers in the eMolecules catalog, ACD users can now prepare their order list using ACD and then quickly, easily and confidently order their compounds from multiple suppliers using the eMolecules fulfillment service. The eMolecules platform enables scientists to obtain real-time information on ready-to-be-shipped compounds and access online management tools for tracking orders and determining delivery times.
MIT researchers have developed a cryptographic system that could help neural networks identify promising drug candidates in massive pharmacological datasets, while keeping the data private. Secure computation done at such a massive scale could enable broad pooling of sensitive pharmacological data for predictive drug discovery.
The architecture of each person’s brain is unique, and differences may influence how quickly people can complete various cognitive tasks.o learn more, scientists are developing a new tool — computational models of the brain — to simulate how the structure of the brain may impact brain activity and, ultimately, human behavior.READ MORE